Breakbone Fever Is Back — And Spreading Further Than Ever

The CDC has issued a global dengue alert for 16 countries. But the alert is only the latest signal in a disease trajectory that has been accelerating for years. Here is what travellers and returning visitors genuinely need to know — including why previous infection makes you more dangerous to yourself, not safer.

The name alone tells you something is wrong. Dengue fever earned its grimmer alias — breakbone fever — from the intensity of the muscle and joint pain that characterises the illness during active infection. It is not a metaphor. The aching is severe enough that patients frequently describe it as feeling like their bones are being broken from the inside. And on March 25, 2026, the United States Centers for Disease Control and Prevention issued a Level 1 global travel alert warning that a higher-than-expected number of US travellers are returning from 16 countries with confirmed dengue infections.

This is not a new disease. It is an old disease accelerating rapidly into new territory — geographically, clinically, and epidemiologically. The 2026 alert is worth taking seriously, but it requires context that most general news coverage does not provide.

The CDC Alert: What It Actually Says

The CDC issued a Level 1 travel notice on March 25, 2026, flagging a significant surge in dengue cases across the Americas, Africa, Asia, and the Pacific. The agency identified a higher-than-expected number of US travellers testing positive after returning from 16 countries. Daily Voice

The full country list covered by the alert is: Afghanistan, Bangladesh, Bolivia, Colombia, Cook Islands, Cuba, Guyana, Maldives, Mali, Mauritania, New Caledonia, Pakistan, Samoa, Sudan, Timor-Leste, and Vietnam. CDC

There have been more than 525 cases of dengue reported in the United States so far in 2026. Officials emphasised that the advisory does not call for cancelling travel plans, but serves as a reminder to take precautions, particularly when visiting tropical and subtropical regions. CBS12

A Level 1 notice is the CDC’s lowest alert tier — “Practice Usual Precautions.” It is not a warning against travel. It is a call to be informed and prepared, issued because the surveillance data shows an unusual cluster of returning traveller cases from specific countries that warrants public attention.

What Dengue Actually Is and Does

Dengue is a viral infection transmitted by Aedes mosquitoes — primarily Aedes aegypti, the same species that transmits Zika and yellow fever. It is more common in tropical and subtropical than in temperate climates. Most people who get infected have no symptoms at all. For those who do, the most common symptoms are high fever, headache, body aches, nausea, and rash. Most people get better within one to two weeks. WHO

The symptoms of clinical dengue — when they occur — are specific and recognisable. Fever arrives suddenly and climbs high. The pain that gives the disease its nickname concentrates behind the eyes, in the muscles, and in the joints with an intensity that is disproportionate to what most travellers would associate with a routine tropical infection. A rash typically appears as the fever peaks or begins to fall.

The severe form is where dengue becomes genuinely dangerous. Symptoms of severe dengue often come after the fever has gone away — a deceptive pattern — and may include severe belly pain, persistent vomiting, bleeding from the gums or nose, blood in the stool or urine, rapid breathing, and extreme fatigue. Severe dengue can be life-threatening within a few hours. WHO

The most critical and counter-intuitive fact about dengue — and the one most travellers do not know — is that previous infection does not protect you. It can make you more vulnerable.

Dengue has four distinct serotypes. Infection with one serotype provides long-term immunity to the same serotype but only transient immunity to the other three. Secondary infection with a different serotype increases the risk of severe dengue significantly. WHO A traveller who had dengue on a previous trip to Thailand and contracts a different serotype in Colombia years later faces a materially higher risk of the severe form than someone who has never been infected. This is not an edge case — it is the primary mechanism driving severe disease in endemic populations.

The Global Trajectory: Not a Blip

The 2026 CDC alert needs to be understood against a backdrop of sustained and accelerating global dengue expansion that has been building for years.

A doubling in the number of global dengue cases has occurred each year since 2021. In December 2023, the WHO assigned its highest level of emergency — Grade 3 — to the global increase in dengue cases, and in June 2024, the WHO Pathogens Prioritization Framework selected dengue virus as a priority pathogen in all six WHO regions. PubMed Central

Between January and September 2024 alone, there were more than 12.7 million dengue cases globally — nearly double the 6.5 million cases reported in all of 2023 — as well as 8,791 deaths. World Economic Forum Brazil has been the primary driver in the Americas, reporting over 133,000 cases and 8 related fatalities since the start of 2026 alone.

The forces driving this expansion are structural rather than cyclical. Dengue outbreaks have traditionally followed a 2 to 5 year cycle as populations lose and regain immunity. But the trend line across those cycles has been upward for decades. Warmer, wetter weather is contributing to the spread, as mosquito populations grow and extend their geographic range. Climate change is enabling Aedes mosquitoes to survive at higher altitudes and at higher latitudes than was possible even a decade ago. World Economic Forum Dengue cases have been confirmed in mainland Europe — France, Italy, Spain — in recent years, in locations where the disease had no history.

The implications for travellers are direct. Dengue risk is no longer confined to the stereotypical tropical beach destination. It is expanding into destinations that travellers may not associate with mosquito-borne disease risk at all.

The Vaccine Situation: Complex and Incomplete

One of the most important things travellers should understand about dengue is that the vaccine landscape is nothing like influenza or hepatitis. There is no simple pre-travel jab available in most Western countries that provides reliable protection.

The only dengue vaccine previously approved in the United States, Dengvaxia, has been discontinued due to low global demand, with remaining supplies in places like Puerto Rico set to expire by mid-2026. Vax-Before-Travel The reason Dengvaxia was restricted is instructive — it was shown to reduce disease in those who had been previously infected, but it increased the risk of severe disease in those who had never been infected and received the vaccine. The paradox of dengue immunology means that a vaccine that creates partial immunity can make a subsequent natural infection more dangerous.

Internationally, Qdenga (TAK-003) from Takeda is now approved in the European Union, Indonesia, Thailand, Brazil, and over 40 countries for children and some adults. WHO prequalified Qdenga in 2024 for children aged 6 to 16 in high-transmission settings, recommending a two-dose schedule. A 4.5-year follow-up from the Phase 3 trial showed cumulative vaccine efficacy of around 60% against confirmed dengue and 84% against hospitalisation. PubMed Central However, Qdenga is not FDA-approved for use in the United States, and most travellers visiting countries on the CDC alert list will not be able to access it through routine pre-travel healthcare consultations in the US or UK.

The practical conclusion for most international travellers is that prevention must rely almost entirely on avoiding mosquito bites — there is no vaccine readily available that provides reliable protection for the typical adult outbound traveller.

Protection: What Actually Works

With no reliable widely accessible vaccine, mosquito avoidance is the primary and most effective protective strategy. The CDC’s guidance is practical and applies to all destinations on the alert list.

Use insect repellent containing DEET, picaridin, IR3535, or oil of lemon eucalyptus on all exposed skin. Apply it after sunscreen, not before. DEET concentrations of 20–30% are recommended for adult travellers. Reapply after swimming or sweating. Aedes mosquitoes are day-biters — unlike malaria-carrying mosquitoes, which are primarily active at dusk and dawn, Aedes aegypti is most active in the hours around sunrise and sunset, but bites throughout the day. This means the protection strategy must be applied during daylight hours, not just at night.

The CDC recommends wearing long sleeves and pants, and staying in places with air conditioning or window screens where possible. CBS12 These recommendations are particularly relevant in budget accommodation settings and during outdoor activities in the early morning or late afternoon.

Remove standing water from accommodation if possible — Aedes mosquitoes breed in small containers of still water, including flower pots, tyres, buckets, and water storage containers. Even a bottle cap of water is enough for breeding. Requesting accommodation with working air conditioning or screened windows materially reduces exposure.

After You Return: The Symptom Window Matters

Health officials urge anyone who develops a fever, headache, or severe body aches within two weeks of returning from a tropical or subtropical region to seek medical attention immediately and to tell their doctor about recent travel. AOL

This instruction is clinically critical for two reasons. First, dengue is commonly misdiagnosed as flu or a non-specific viral illness, particularly in settings where clinicians have little experience with tropical diseases. Telling your doctor about your travel history is not optional context — it is the diagnostic information that determines whether the right tests are ordered. Second, the progression to severe dengue can be rapid, occurring in the first 24 to 48 hours after the fever breaks. A patient who is discharged home with a “viral illness” diagnosis and then develops severe abdominal pain and bleeding gums the following day needs to return to hospital immediately.

Warning signs requiring emergency care include severe stomach pain, persistent vomiting, bleeding from the gums or nose, blood in the stool or urine, rapid breathing, and extreme fatigue. AOL Do not wait to see if these symptoms resolve on their own.

There is no specific antiviral treatment for dengue. Management is supportive — rest, hydration, and paracetamol (acetaminophen) for fever and pain. Aspirin and ibuprofen are specifically contraindicated because they increase bleeding risk, which is critically important given dengue’s potential to cause haemorrhage in its severe form.

The Countries on the List — And the Ones Not On It

A final important note about the CDC alert: the 16 listed countries represent the locations where higher-than-expected cases are being detected in returning US travellers right now. They do not represent the full universe of dengue risk.

Dengue is endemic in most of sub-Saharan Africa, South and Southeast Asia, Central and South America, the Pacific islands, and large parts of the Caribbean. Brazil — the country with by far the highest current case burden in the Americas — is not on the 2026 alert list. Neither is Thailand, Indonesia, the Philippines, India, or any other country where dengue transmission is intense and year-round.

The alert list reflects US traveller surveillance data — it tells you where Americans are currently becoming infected at higher-than-expected rates, not where dengue doesn’t exist. Any traveller heading to a tropical or subtropical destination should consider dengue risk standard preparation, regardless of whether their specific destination appears on the current alert.

KEY INSIGHTS SUMMARY

The CDC issued a Level 1 Global Dengue Travel Health Notice on March 25, 2026, identifying 16 countries where higher-than-expected dengue cases are being detected among returning US travellers: Afghanistan, Bangladesh, Bolivia, Colombia, Cook Islands, Cuba, Guyana, Maldives, Mali, Mauritania, New Caledonia, Pakistan, Samoa, Sudan, Timor-Leste, and Vietnam. More than 525 dengue cases have been reported in the US so far in 2026.

A Level 1 alert is the CDC’s lowest tier — it does not advise against travel. It is a call to take standard precautions seriously.

Dengue has four distinct serotypes. Prior infection with one serotype does not protect against the others and actually increases the risk of severe dengue upon reinfection with a different serotype. A traveller who has had dengue before is at higher — not lower — risk of severe illness upon a subsequent infection.

The global dengue burden has doubled each year since 2021. The WHO assigned its highest emergency grade to the dengue surge in December 2023. Over 12.7 million cases were reported globally in the first nine months of 2024, nearly double the 2023 total.

No vaccine is readily accessible for most adult travellers from the US or UK. Dengvaxia has been discontinued in the US. Qdenga is approved in the EU and 40+ countries but not FDA-approved for US use and is not part of standard pre-travel vaccination protocols in most Western healthcare settings.

Prevention depends entirely on mosquito bite avoidance: DEET-based repellents applied during daylight hours, long-sleeved clothing, air-conditioned or screened accommodation, and elimination of standing water. Aedes mosquitoes bite throughout the day — nighttime protection alone is insufficient.

Aspirin and ibuprofen are specifically contraindicated for dengue — they increase bleeding risk. Paracetamol is the recommended pain and fever management.

Anyone developing fever, severe headache, joint or muscle pain, or rash within 14 days of returning from a tropical destination must seek immediate medical attention and disclose their travel history. The warning signs of severe dengue — abdominal pain, persistent vomiting, bleeding from gums or nose, blood in stool or urine — require emergency care and may appear after the initial fever subsides, not during it.

The alert list reflects current US traveller surveillance data, not the full scope of dengue risk. Brazil, Thailand, Indonesia, India, the Philippines, and most of tropical Southeast Asia and Central America are not on the current list despite carrying high endemic transmission. Any traveller to a tropical destination should treat dengue prevention as standard pre-travel preparation.